Shuichi Kaneko

Shuichi Kaneko

Auto-generated profile, based on publicly available information

Shuichi Kaneko

Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa, Ishikawa, Japan

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2005 in Gut
Verified
Journal Article
Open access
PDF file
HIH Iida
H Iida
MHM Honda
M Honda
HKH F Kawai
H F Kawai
TYT Yamashita
T Yamashita
YSY Shirota
Y Shirota
SKS Kaneko
S Kaneko
Background and aims: α-Fetoprotein (AFP), a tumour marker for hepatocellular carcinoma (HCC), is associated with poor prognosis. Using cDNA microarray analysis, we previously found that ephrin-A1, an angiogenic factor, is the most differentially overexpressed gene in AFP producing hepatoma cell lines. In the present study, we investigated the significance of ephrin-A1 expression in HCC. Methods: We examined ephrin-A1 expression and its effect on cell proliferation and gene expression in five AFP producing hepatoma cell lines, three AFP negative hepatoma cell lines, and 20 human HCC specimens. Results: Ephrin-A1 expression levels were lowest in normal liver tissue, elevated in cirrhotic tissue, and further elevated in HCC specimens. Ephrin-A1 expression was strongly correlated with AFP expression ( r = 0.866). We showed that ephrin-A1 induced expression of AFP. This finding implicates ephrin-A1 in the mechanism of AFP induction in HCC. Ephrin-A1 promoted the proliferation of ephrin-A1 underexpressing HLE cells, and an ephrin-A1 antisense oligonucleotide inhibited the proliferation of ephrin-A1 overexpressing Huh7 cells. Thus ephrin-A1 affects hepatoma cell growth. cDNA microarray analysis showed that ephrin-A1 induced expression of genes related to the cell cycle (p21), angiogenesis (angiopoietin 1 and thrombospondin 1), and cell-cell interactions (Rho, integrin, and matrix metalloproteinases) in cultured hepatoma cells. These ephrin-A1 induced genes are also activated in HCC tissues that overexpress AFP. Conclusion: These findings suggest that the poor prognosis of patients with AFP producing HCC is partially caused by ephrin-A1 expression, which induces expression of genes related to tumour cell growth, angiogenesis, invasion, and metastasis.

20 December 2005 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
EMEishiro Mizukoshi
Eishiro Mizukoshi
YNYasunari Nakamoto
Yasunari Nakamoto
HTHirokazu Tsuji
Hirokazu Tsuji
TYTatsuya Yamashita
Tatsuya Yamashita
SKShuichi Kaneko
Shuichi Kaneko
α‐Fetoprotein (AFP) has been proposed as a potential target forT‐cell‐based immunotherapy for hepatocellular carcinoma (HCC), but the number of its epitopes that have been identified is limited and the status of AFP‐specific immunological responses in HCC patients has not been well‐characterized. To address the issue, we examined the possibility of inducing AFP‐specific cytotoxic T cells (CTLs) using novel HLA‐A*2402‐restricted T‐cell epitopes (HLA, human leukocyte antigen) derived from AFP and then analyzed the relationship between its frequency of occurrence and clinical features associated with patients having HCC. Five AFP‐derived peptides containing HLA‐A*2402 binding motifs and showing high binding affinity to HLA‐A*2402 induced CTLs to produce IFN‐γ and kill an AFP‐producing hepatoma cell line. The frequency of AFP‐specific CTLs was 30–190 per 1 × 106 peripheral blood mononuclear cells, which was the same as that of other immunogenic cancer associated antigen‐derived epitopes. Analyses of the relationships between AFP‐specific CTL responses and clinical features of patients with HCC revealed that AFP epitopes were more frequently recognized by CTLs in patients with advanced HCC correlating to tumor factors or the stage of TNM classification. The analyses of CTL responses before and after HCC treatments showed that the treatments changed the frequency of AFP‐specific CTLs. In conclusion, we identified five HLA‐A*2402‐restrictedT‐cell epitopes derived from AFP. The newly identified AFP epitopes could be a valuable component of HCC immunotherapy and for analyzing host immune responses to HCC.

1 March 2000 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
TYTaro Yamashitaab
Taro Yamashitaab
SHShin-Ichi Hashimoto
Shin-Ichi Hashimoto
SKShuichi Kaneko
Shuichi Kaneko
SNShigenori Nagaib
Shigenori Nagaib
NTNobuaki Toyodab
Nobuaki Toyodab
KMKouji Matsushimab
Kouji Matsushimab

26 March 2004 in Diabetologia
Verified
Journal Article
Closed access
PDF file
TTT. Takamura
T. Takamura
MSM. Sakurai
M. Sakurai
TOT. Ota
T. Ota
HAHitoshi Ando
Hitoshi Ando
SKS. Kaneko
S. Kaneko
MHM. Honda
M. Honda

1 May 2004 in Cancer Research
Verified
Journal Article
Closed access
PDF file
YNYasunari Nakamoto
Yasunari Nakamoto
TSTakashi Suda
Takashi Suda
TMTakashi Momoi
Takashi Momoi
SKShuichi Kaneko
Shuichi Kaneko
The immune response to hepatitis viruses is believed to be involved in the development of chronic hepatitis; however, its pathogenetic potential has not been clearly defined. The current study, using a transgenic mouse model of chronic hepatitis B, was designed to determine the relative contributions of the immune cell subsets to the progression of liver disease that induces hepatocellular carcinogenesis. Hepatitis B virus transgenic mice were adoptively transferred with CD4+ and CD8+ T cell-enriched or -depleted and B cell-depleted splenocytes obtained from hepatitis B surface antigen-primed, syngeneic nontransgenic donors. The resultant liver disease, hepatocyte apoptosis, regeneration, and tumor development were assessed and compared with the manifestations in mice that had received unfractionated spleen cells. Transfer of CD8+-enriched splenocytes caused prolonged disease kinetics, and a marked increase in the extent of hepatocyte apoptosis and regeneration. In 12 of 14 mice the transfer resulted in multiple hepatocellular carcinomas (HCCs) comparable with the manifestations seen in the mice transferred with total splenocytes. In contrast, mice that had received CD4+-enriched cells demonstrated lower levels of liver disease and developed fewer incidences of HCC (4 of 17). The experiment also revealed that all of the groups of mice complicated with HCC developed comparable mean numbers and sizes of tumors. B-cell depletion had no effect on disease kinetics in this model. Taken together, these results demonstrate that the pathogenetic events induced by CD8+ T-cell subset are primarily responsible for the induction of chronic liver disease that increases tumor incidence, suggesting their potential in triggering the process of hepatocarcinogenesis.

1 November 1999 in Hepatology
Verified
Journal Article
Open access
PDF file
EMEishiro Mizukoshi
Eishiro Mizukoshi
SKShuichi Kaneko
Shuichi Kaneko
KKKyosuke Kaji
Kyosuke Kaji
STShuichi Terasaki
Shuichi Terasaki
EMEiki Matsushita
Eiki Matsushita
KKKenichi Kobayashi
Kenichi Kobayashi
Human serum contains a soluble form of interferon alfa/beta (sIFN α/β) receptors, the functional and clinical significance of which has not been investigated in patients with chronic hepatitis C. In the present study, serum levels of sIFN α/β receptor were assessed in 81 patients with chronic hepatitis C and correlated with the effectiveness of IFN therapy in these patients. Serum levels of sIFN α/β receptor were significantly higher in patients with chronic hepatitis C than in healthy control patients (P < .0001). In these patients, serum levels of sIFN α/β receptor were correlated with those of alanine transaminase (ALT) (P < .05), (2′-5′)serum oligo(A) synthetase (2-5AS) (P < .0001), and pathological stages of liver fibrosis (P < .01). In 55 patients with chronic hepatitis C who underwent IFN therapy, there was an inverse correlation between the pretherapeutic serum levels of sIFN α/β receptor and the rate of increase in serum levels of 2-5AS after the start of IFN (P < .01). Pretherapeutic serum levels of sIFN α/β receptor were significantly lower in patients who showed sustained response to IFN therapy compared with those who did not respond to the therapy (P < .05). Multivariate analysis showed that low levels of serum sIFN α/β receptor (≤4.0 ng/mL) (P < .05) and serological hepatitis C virus genotype II (P < .05) were independent variables contributing to sustained response to IFN therapy. Thus, pretherapeutic serum levels of sIFN α/β receptor were correlated with the effectiveness of IFN therapy, suggesting that sIFN α/β receptor suppresses the effectiveness of IFN therapy in patients with chronic hepatitis C.